Immuno-Oncology Resource Center

Immuno-Oncology Resource Center

Source:

Press Release

April 22, 2022
1 min read
Save

FDA grants fast track designation to gamma-delta T-cell therapy for advanced lymphoma

Source:

Press Release

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA granted fast track designation to ADI-001 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma.

ADI-001 (Adicet Bio) is an allogeneic gamma-delta T-cell therapy derived from donor cells that is genetically engineered to express a CD20-directed chimeric antigen receptor.

Gene therapy image with collection tubes.
Source: Adobe Stock.

The FDA's fast track designation helps to expedite development, review and potential approval of treatments for serious or life-threatening diseases.

The investigational cell therapy is currently being evaluated as part of the GLEAN-1 trial, a phase 1, U.S.-based multicenter dose-escalation study to determine its safety and tolerability for the treatment of patients with relapsed or refractory B-cell malignancies who have received at least two prior lines of treatment.

“Fast track designation represents an important milestone in the clinical development of ADI-001,” Chen Schor, president and CEO of Adicet Bio, said in a company-issued press release.

“We believe ADI-001 is unique in that it is designed to target malignant B cells by leveraging the innate and adaptive receptors found naturally on gamma-delta T cells with the added benefit of an engineered anti-CD20 CAR,” he added. “We remain optimistic about the potential of our program and look forward to reporting additional data from the phase 1 trial of ADI-001 in the first half of 2022.”